MedTrace Logo

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-07-17

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study comparing the efficacy of nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular disease risk in subjects with early vascular disease. Approximately 75 subjects with borderline/elevated blood pressures and impaired endothelial function, as measured by arterial elasticity scores, will be recruited and assigned to treatment groups using a block randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or placebo, and then followed for 9 months.

Conditions

Interventions

DRUG

Nebivolol

5 mg daily or 10 mg daily

DRUG

atenolol

25 mg daily or 50 mg daily

DRUG

placebo

one tablet daily

Sponsors & Collaborators

Principal Investigators

  • Jay N Cohn, MD · University of Minnesota Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2016-10-31
Completion
2016-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522950 on ClinicalTrials.gov